MCID: HYP072
MIFTS: 49

Hypersensitivity Reaction Type Iii Disease

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iii Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iii Disease:

Name: Hypersensitivity Reaction Type Iii Disease 12 15
Immune Complex Diseases 56 45 74
Type Iii Hypersensitivity Reaction Disease 17
Immune Complex Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1557
MeSH 45 D007105
UMLS 74 C0020951

Summaries for Hypersensitivity Reaction Type Iii Disease

Disease Ontology : 12 A hypersensitivity reaction disease that is characterized by the accumulation of antigen-antibody immune complexes, causing an inflammatory response and injury.

MalaCards based summary : Hypersensitivity Reaction Type Iii Disease, also known as immune complex diseases, is related to hypersensitivity vasculitis and membranoproliferative glomerulonephritis. An important gene associated with Hypersensitivity Reaction Type Iii Disease is HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Dapsone and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and bone marrow, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Related Diseases for Hypersensitivity Reaction Type Iii Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iii Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 hypersensitivity vasculitis 31.2 C3 C4A CD79A CRP HSP90AA1 MEFV
2 membranoproliferative glomerulonephritis 30.7 ALB C3 C4A CD79A CFP ICAM1
3 complement deficiency 29.8 C3 C4A CFP
4 lupus erythematosus 29.5 C3 C4A C4B TNF
5 palindromic rheumatism 29.5 CRP MEFV TNF
6 pustulosis palmaris et plantaris 29.3 CD79A SELE TNF
7 typhoid fever 29.0 ALB CRP IL6 TNF
8 inflammatory bowel disease 28.6 CRP IL6 MPO TNF
9 myeloma, multiple 28.6 ALB CD79A CRP HSP90AA1 IL6 TNF
10 vasculitis 28.3 CRP ICAM1 MEFV MPO SELE TNF
11 rheumatoid arthritis 28.2 CRP ICAM1 IL6 SELE TNF
12 synovitis 28.2 CRP ICAM1 IL6 SELE TNF
13 glomerulonephritis 28.1 ALB C3 C4A C4B CD79A CFP
14 systemic lupus erythematosus 26.7 ALB C3 C4A C4B CD79A CRP
15 arthus reaction 11.3
16 c1q deficiency 10.9
17 complement component c1s deficiency 10.9
18 focal dermal hypoplasia 10.5 ALB CD79A
19 parotitis 10.5 ALB CD79A
20 root caries 10.5 ALB CD79A
21 arteriolosclerosis 10.5 C3 CD79A
22 abdominal tuberculosis 10.4 ALB CRP
23 pyuria 10.4 ALB CRP
24 gastrointestinal tuberculosis 10.4 ALB CRP
25 decubitus ulcer 10.4 ALB CRP
26 monoclonal paraproteinemia 10.4 HSP90AA1 MPO
27 epilepsy, familial temporal lobe, 2 10.4 C4A C4B
28 acute maxillary sinusitis 10.4 C3 CRP
29 acquired angioedema 10.4 C3 CRP
30 pasteurellosis 10.4 ALB MPO
31 juvenile dermatitis herpetiformis 10.4 C4A C4B
32 pleural empyema 10.4 CD79A CRP
33 chronic monocytic leukemia 10.4 C3 MPO
34 phototoxic dermatitis 10.4 C3 ICAM1
35 mononeuritis multiplex 10.3 CRP MPO
36 aortitis 10.3 CRP MPO
37 mediastinitis 10.3 CRP MPO
38 diffuse glomerulonephritis 10.3 ALB CFP
39 complement component 3 deficiency 10.3 C3 CFP
40 c3 glomerulopathy 10.3 C3 CFP
41 orthostatic proteinuria 10.3 ALB C3 HSP90AA1
42 autoinflammation, panniculitis, and dermatosis syndrome 10.3 MEFV TNF
43 erysipelas 10.3 MEFV TNF
44 burns 10.3 ALB TNF
45 cow milk allergy 10.3 CD79A TNF
46 clonorchiasis 10.3 CD79A TNF
47 subacute bacterial endocarditis 10.2 CFP MPO
48 hymenolepiasis 10.2 ICAM1 SELE
49 mooren's ulcer 10.2 ICAM1 SELE
50 plummer's disease 10.2 ICAM1 SELE

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iii Disease:



Diseases related to Hypersensitivity Reaction Type Iii Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iii Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 ALB C3 C4A CD79A HSP90AA1 SELE

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iii Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.09 C3 C4B CFP CRP ICAM1 IL6
2 cellular MP:0005384 10.06 ALB C3 CD79A HSP90AA1 ICAM1 IL6
3 homeostasis/metabolism MP:0005376 10.03 ALB C3 C4B CD79A CFP CRP
4 hematopoietic system MP:0005397 9.97 C3 C4B CD79A ICAM1 IL6 MEFV
5 immune system MP:0005387 9.93 C3 C4B CD79A CFP CRP HSP90AA1
6 digestive/alimentary MP:0005381 9.85 ALB C3 C4B ICAM1 IL6 TNF
7 liver/biliary system MP:0005370 9.56 ALB C3 C4B CD79A IL6 MEFV
8 mortality/aging MP:0010768 9.36 ALB C3 C4B CFP HSP90AA1 ICAM1

Drugs & Therapeutics for Hypersensitivity Reaction Type Iii Disease

Drugs for Hypersensitivity Reaction Type Iii Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4,Phase 2 80-08-0 2955
2
leucovorin Approved Phase 4,Phase 2 58-05-9 143 6006
3
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 53-03-2 5865
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 22916-47-8 4189
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
9
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 6473866 445643 439492
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
11
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7
12 Antimalarials Phase 4,Phase 2
13 Folic Acid Antagonists Phase 4,Phase 2
14 Vitamin B9 Phase 4,Phase 2
15 Antiparasitic Agents Phase 4,Phase 2
16 Antiprotozoal Agents Phase 4,Phase 2
17 Vitamin B Complex Phase 4,Phase 2
18 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
19 Folate Phase 4,Phase 2
20 Anti-Bacterial Agents Phase 4,Phase 2,Not Applicable
21 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1,Not Applicable
23 glucocorticoids Phase 4,Phase 2,Phase 1,Not Applicable
24 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Not Applicable
25 Hormones Phase 4,Phase 2,Phase 1,Not Applicable
26 Calcineurin Inhibitors Phase 4,Phase 2,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
29 Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
30 Protein Kinase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
31 Prednisolone acetate Phase 4,Phase 2,Not Applicable
32 Autonomic Agents Phase 4,Phase 2,Not Applicable
33 Antirheumatic Agents Phase 4,Phase 2,Not Applicable
34 Dermatologic Agents Phase 4,Not Applicable
35 Antifungal Agents Phase 4,Phase 2,Not Applicable
36 Gastrointestinal Agents Phase 4,Phase 2,Not Applicable
37 Neuroprotective Agents Phase 4,Phase 2,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable
39 Methylprednisolone Acetate Phase 4,Phase 2,Not Applicable
40 Antiemetics Phase 4,Phase 2,Not Applicable
41 Cyclosporins Phase 4,Not Applicable
42 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
43 Imatinib Mesylate Phase 4,Phase 2,Phase 1,Not Applicable 220127-57-1 123596
44
Cladribine Approved, Investigational Phase 2, Phase 3,Phase 3 4291-63-8 20279
45
Omalizumab Approved, Investigational Phase 2, Phase 3 242138-07-4
46
Denosumab Approved Phase 3 615258-40-7
47 2-chloro-3'-deoxyadenosine Phase 2, Phase 3,Phase 3
48 Histamine Antagonists Phase 2, Phase 3,Phase 3
49 Anti-Allergic Agents Phase 2, Phase 3
50 Anti-Asthmatic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
3 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4 Imatinib Mesylate
4 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
5 Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Unknown status NCT01602939 Phase 2, Phase 3 Cladribine and pegylated interpheron alpha-2a
6 Study on Mastocytosis for Rupatadine Treatment Completed NCT01481909 Phase 2, Phase 3 Rupatadin
7 The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Completed NCT01333293 Phase 2, Phase 3 injections
8 Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Completed NCT00814073 Phase 3 Masitinib;Placebo
9 Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis Recruiting NCT03401060 Phase 3 Denosumab;Placebo
10 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2 Midostaurin,
11 Evaluation of Response of Dasatinib to Treat Mastocytosis Unknown status NCT00979160 Phase 2 Dasatinib
12 Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura Unknown status NCT01104428 Phase 2 Placebo;"ziying" granules
13 A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines Completed NCT02956746 Phase 1, Phase 2
14 Treatment of Indolent Systemic Mastocytosis With PA101 Completed NCT02478957 Phase 2 PA101;Placebo
15 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Completed NCT01807598 Phase 2 Brentuximab vedotin
16 Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation Completed NCT01266369 Phase 2 masitinib
17 Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Completed NCT00831974 Phase 2 masitinib (AB1010);masitinib (AB1010)
18 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Completed NCT00782067 Phase 2 Midostaurin (PKC412)
19 Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis Completed NCT00769587 Phase 2 thalidomide
20 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2 Ontak (Denileukin Diftitox)
21 Efficacy and Safety of TF002 in Cutaneous Mastocytosis Completed NCT00457288 Phase 2 TF 002
22 Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Completed NCT00449748 Phase 2 RAD001 (Everolimus)
23 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
24 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Completed NCT00233454 Phase 2 Midostaurin
25 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
26 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
27 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
28 Stem Cell Transplantation to Treat Systemic Mastocytosis Completed NCT00006413 Phase 2
29 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
30 Flu Vaccine Response in Patients on Biologic Therapies Recruiting NCT03277703 Phase 2
31 Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis Recruiting NCT03770273 Phase 2
32 (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis Recruiting NCT03731260 Phase 2 Avapritinib;Placebo
33 (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Recruiting NCT03580655 Phase 2 Avapritinib
34 Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment Recruiting NCT03591471 Phase 1, Phase 2 Glycosides Of Tripterygium Wilfordii Hook(GTW);Sulfotanshinone Sodium Injection;Chinese herbs based on syndrome differentiation;Prednisone Acetate Tablets;Benazepril Hydrochloride Tablets;Low Molecular Weight Heparin Calcium Injection;Dipyridamole Tab 25 MG;Chinese medicine placebo
35 A Randomized Multicenter Study for Isolated Skin Vasculitis Recruiting NCT02939573 Phase 2 Colchicine;Dapsone;Azathioprine
36 The Research of Standard Diagnosis and Treatment for Severe HSP in Children Recruiting NCT02540720 Phase 2 Dexamethasone;Gamma globulin
37 The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children Recruiting NCT02532790 Phase 2 Prednisone;ACEI
38 The Research of Standard Diagnosis and Treatment for HSPN in Children Recruiting NCT02532777 Phase 2 Prednisone;Cyclophosphamide(CTX);Mycophenolate mofetil(MMF);Leflunomide(LEF);Angiotensin-converting enzyme inhibitor(ACEI);Methylprednisolone
39 SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) Recruiting NCT02268253 Phase 1, Phase 2 SL-401
40 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
41 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
42 CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKEs) for High Risk Heme Malignancies Not yet recruiting NCT03214666 Phase 1, Phase 2 161533 Trike Phase I;161533 Trike Phase II
43 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Terminated NCT02415608 Phase 2 Ibrutinib
44 Cromoglicate in Mastocytosis Terminated NCT01701843 Phase 2 Cromoglicate;Placebo
45 Obatoclax for Systemic Mastocytosis Terminated NCT00918931 Phase 2 Obatoclax Mesylate
46 A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants Completed NCT02290340 Phase 1 Placebo;MEDI8897 10 mg;MEDI8897 25 mg;MEDI8897 50 mg
47 Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults Completed NCT02255760 Phase 1 MEDI3902 - Dose 1;MEDI3902 - Dose 2;MEDI3902 - Dose 3;MEDI3902 - Dose 4
48 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 Completed NCT02808793 Phase 1 AK002
49 (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1 Avapritinib
50 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618

Search NIH Clinical Center for Hypersensitivity Reaction Type Iii Disease

Cochrane evidence based reviews: immune complex diseases

Genetic Tests for Hypersensitivity Reaction Type Iii Disease

Anatomical Context for Hypersensitivity Reaction Type Iii Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iii Disease:

42
Bone, Skin, Bone Marrow, Kidney, Neutrophil, Heart, Testes

Publications for Hypersensitivity Reaction Type Iii Disease

Articles related to Hypersensitivity Reaction Type Iii Disease:

(show all 32)
# Title Authors Year
1
Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases. ( 19852746 )
2009
2
A full complement of receptors in immune complex diseases. ( 12488423 )
2002
3
[Therapeutic plasmapheresis in immune complex diseases]. ( 7985137 )
1994
4
Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. ( 8098488 )
1993
5
Immune complex diseases. ( 8424984 )
1993
6
Immune complex diseases. ( 2151123 )
1990
7
Cationic polyelectrolytes: a new look at their possible roles as opsonins, as stimulators of respiratory burst in leukocytes, in bacteriolysis, and as modulators of immune-complex diseases (a review hypothesis). ( 2961690 )
1987
8
Complement and immune complex diseases. ( 2944500 )
1986
9
Detection of complement activation in immune complex diseases: six methods compared. ( 2946496 )
1986
10
Neutrophil-mediated cellular cytotoxicity triggered by immobilized aggregated IgG: an in vitro model of cell injury during immune complex diseases. ( 6096393 )
1984
11
Treatment of immune complex diseases. ( 6239985 )
1984
12
Complement-mediated inhibition of immune precipitation in patients with immune complex diseases. ( 6220848 )
1983
13
Plasma exchange and immune complex diseases: the predictability of immune complexes removal to clinical response. ( 6460383 )
1982
14
The effect of plasma exchange on the in vitro monocyte function of patients with immune complex diseases. ( 6459197 )
1981
15
Factors influencing the development of immune-complex diseases. ( 6461275 )
1981
16
Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. ( 6454615 )
1981
17
Coexisting immune complex diseases in atopy. ( 6449893 )
1980
18
Is autoimmunity a common denominator in immune complex diseases? ( 6101634 )
1980
19
Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions. ( 6447230 )
1980
20
Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. ( 6449819 )
1980
21
Biochemical aspects of immune complex formation and immune complex diseases. ( 6451188 )
1980
22
Pathophysiologicl aspects of immune complex diseases part i. interaction with plasma enzyme systems, cell membranes and the immune response. ( 7392533 )
1980
23
A nephelometric study of the reaction of monoclonal rheumatoid factor with heat aggregated gamma globulin and sera from patients with immune complex diseases. ( 92379 )
1979
24
Serum complement profile in human leprosy and its comparison with immune complex diseases. ( 147246 )
1977
25
Editorial: Are the inflammatory bowel diseases immune complex diseases? ( 128486 )
1976
26
Proceedings: Models of immune complex diseases and the role of antibody affinity. ( 129487 )
1976
27
Canine immune complex diseases. ( 136591 )
1976
28
Immunity. II. Immune complex diseases. ( 4277523 )
1974
29
Immune complex diseases. ( 4264709 )
1972
30
Virus-associated immunopathology: animal models and implications for human disease. 1. Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated immunologic injury. ( 4404992 )
1972
31
Immune complex diseases. I. Pathological changes in the kidneys of BALB-c mice neonatally infected with Moloney leukaemogenic and murine sarcoma viruses. ( 4333814 )
1971
32
Immune complex diseases. ( 4398333 )
1971

Variations for Hypersensitivity Reaction Type Iii Disease

Expression for Hypersensitivity Reaction Type Iii Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iii Disease.

Pathways for Hypersensitivity Reaction Type Iii Disease

Pathways related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 C3 C4A C4B CD79A CFP CRP
2
Show member pathways
12.96 C3 HSP90AA1 IL6 MEFV TNF
3
Show member pathways
12.79 C3 C4A HSP90AA1 ICAM1 IL6 TNF
4 12.11 C4A C4B IL6 TNF
5
Show member pathways
12.05 C3 C4A C4B CRP
6 12.03 HSP90AA1 ICAM1 SELE TNF
7 11.96 C3 C4A C4B
8 11.93 CD79A IL6 MPO TNF
9 11.92 HSP90AA1 ICAM1 IL6 TNF
10 11.89 ICAM1 IL6 TNF
11 11.89 ICAM1 IL6 SELE TNF
12
Show member pathways
11.86 C3 C4A C4B CFP
13 11.83 ICAM1 IL6 SELE TNF
14
Show member pathways
11.78 C3 C4A C4B CFP CRP
15
Show member pathways
11.77 ALB CRP ICAM1 IL6 MPO TNF
16 11.76 ICAM1 IL6 TNF
17 11.71 HSP90AA1 ICAM1 IL6 SELE
18 11.57 C3 C4A C4B ICAM1
19
Show member pathways
11.56 ICAM1 IL6 SELE TNF
20 11.53 C3 IL6 TNF
21 11.49 HSP90AA1 IL6 TNF
22 11.47 ICAM1 IL6 TNF
23 11.4 ICAM1 IL6 SELE TNF
24 11.35 ICAM1 IL6 MPO TNF
25 11.02 ICAM1 IL6 SELE TNF
26 10.98 IL6 TNF
27 10.97 CRP IL6 TNF
28 10.9 C3 C4A C4B IL6 TNF
29 10.86 ICAM1 MPO TNF

GO Terms for Hypersensitivity Reaction Type Iii Disease

Cellular components related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 ALB C3 C4A C4B HSP90AA1 ICAM1
2 extracellular region GO:0005576 9.65 ALB C3 C4A C4B CFP CRP
3 membrane raft GO:0045121 9.62 CD79A ICAM1 SELE TNF
4 blood microparticle GO:0072562 9.56 ALB C3 C4A C4B
5 endoplasmic reticulum lumen GO:0005788 9.55 ALB C3 C4A CFP IL6
6 extracellular space GO:0005615 9.36 ALB C3 C4A C4B CFP CRP

Biological processes related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.92 C3 C4A C4B CD79A MEFV
2 post-translational protein modification GO:0043687 9.88 ALB C3 C4A IL6
3 cytokine-mediated signaling pathway GO:0019221 9.85 HSP90AA1 ICAM1 IL6 TNF
4 innate immune response GO:0045087 9.8 C3 C4A C4B CFP CRP MEFV
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.79 ICAM1 IL6 TNF
6 negative regulation of endopeptidase activity GO:0010951 9.79 C3 C4A C4B
7 cellular protein metabolic process GO:0044267 9.76 ALB C3 C4A IL6
8 defense response to Gram-positive bacterium GO:0050830 9.73 CRP IL6 TNF
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 HSP90AA1 IL6 TNF
10 complement activation, classical pathway GO:0006958 9.71 C3 C4A C4B CRP
11 regulation of complement activation GO:0030449 9.67 C3 C4A C4B CFP
12 positive regulation of chemokine production GO:0032722 9.61 IL6 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 HSP90AA1 ICAM1 TNF
14 leukocyte tethering or rolling GO:0050901 9.6 SELE TNF
15 positive regulation of glial cell proliferation GO:0060252 9.59 IL6 TNF
16 negative regulation of growth of symbiont in host GO:0044130 9.58 MPO TNF
17 complement activation, alternative pathway GO:0006957 9.57 C3 CFP
18 complement activation GO:0006956 9.56 C3 C4A C4B CFP
19 opsonization GO:0008228 9.51 C4B CRP
20 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.49 ICAM1 TNF
21 positive regulation of neuroinflammatory response GO:0150078 9.48 IL6 TNF
22 negative regulation of lipid storage GO:0010888 9.33 CRP IL6 TNF
23 inflammatory response GO:0006954 9.23 C3 C4A C4B CRP IL6 MEFV
24 positive regulation of apoptotic cell clearance GO:2000427 9.13 C3 C4A C4B

Molecular functions related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 complement component C1q binding GO:0001849 8.96 C4A CRP
2 endopeptidase inhibitor activity GO:0004866 8.8 C3 C4A C4B

Sources for Hypersensitivity Reaction Type Iii Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....